TAG:
smear test
No Disruptive Technology In Lab Industry’s Future
By Robert Michel | From the Volume X No. 14 – October 20, 2003 Issue
CEO SUMMARY: As new diagnostic technologies move through the development pipeline and into widespread clinical use, the scientific knowledge and skill sets needed by laboratory staff and management will change. The emphasis in laboratory medicine will evolve to include more molecular tech…
Are Two Blood Brothers Using Economic Clout?
By Robert Michel | From the Volume X No. 10 – July 28, 2003 Issue
CEO SUMMARY: Quest Diagnostics Incorporated and Laboratory Corporation of America now dominate the national marketplace for testing referred by physicians’ offices. Release of their second quarter earnings reports provides the first look at their performance following the acquisitions i…
Bio-Reference Labs, Quest Diagnostics, TriPath Imaging, Specialty Labs, SARS
By Robert Michel | From the Volume X No. 4 – March 24, 2003 Issue
BIO-REFERENCE LABS POSTS 20% INCREASE IN ANNUAL NET REVENUE LAST YEAR’S FRENZY of laboratory acquisitions left Bio-Reference Laboratories, Inc. of Elmwood Park, New Jersey as the nation’s third-largest public laboratory company focused primarily on physicians’ office t…
Jamaica Med Techs, Kaiser Permanente, Cytyc, Myriad Genetics, Bayer, CLMA
By Robert Michel | From the Volume X No. 2 – February 10, 2003 Issue
MEDICAL TECHNOLOGISTS IN JAMAICA STAGE WALK-OUT IN JANUARY LABORATORY TECHS ARE NOT KNOWN to be a radical component of the labor movement. But that doesn’t seem to be the case in Jamaica, where more than 80 of that country’s medical technologists walked off their jobs twice in January in…
Major Changes at Dade Behring Soon to Be Visible In Lab Market
By Robert Michel | From the Volume IX No. 15 – October 28, 2002 Issue
Its recent financial restructuring now complete, Dade Behring prepares a “brand building” campaign CEO SUMMARY: Dade Behring is poised to become a tough and high-profile competitor in the laboratory diagnostics marketplace. Earlier this month,…
High Cost of New Assays Stretching Lab Budgets
By Robert Michel | From the Volume IX No. 7 – May 13, 2002 Issue
CEO SUMMARY: Growing numbers of hospital labs report that higher costs of new diagnostic tests have become a new management problem. That’s because diagnostic manufacturers are developing tests around a new business model, one that calls for higher pricing based on a premise of higher c…
New Lab Test Technology Must Meet Five Payer Requirements
By Robert Michel | From the Volume IX No. 5 – April 1, 2002 Issue
HOSPITALS ARE NOT THE ONLY healthcare player wary of the high cost of new diagnostic test technologies. Insurance companies all over the United States have increased their scrutiny of new medical technology, including laboratory tests. In a visit to Wall Street last week, THE DARK REPORT attended …
Cytyc Acquires Digene To Expand Product Line
By Robert Michel | From the Volume IX No. 4 – March 11, 2002 Issue
CEO SUMMARY: Cytyc Corporation will pay more than one half billion dollars to purchase Digene, Inc., and its DNA Capture HPV test. For Cytyc, this may prove to be a strategic masterstroke. In the short term, it alters the competitive balance in the market for liquid preparation Pap testin…
Tripath Imaging Ready To Roil Pap Test Market
By Robert Michel | From the Volume VIII No. 17 – December 17, 2001 Issue
CEO SUMMARY: Single-handedly, Cytyc Corporation has built the market for thin-layer Pap smear testing. Executives at TriPath Imaging are now ready to challenge Cytyc’s dominance by offering what they believe is a different value proposition to labs: an automated liquid preparation syste…
“November 5, 2001 Intelligence: Late Breaking Lab News”
By Robert Michel | From the Volume VIII No. #15 – November 5, 2001 Issue
It’s a milestone in the Pap smear testing marketplace. Cytyc Corporation, in its third quarter financial report, now claims its Thin-Prep® product has 51% of the national market for Pap testing. Estimates are that 55 million Pap tests are done annually in the United States. A 51% …
CURRENT ISSUE

Volume XXXII, No. 6 – April 21, 2025
Now that a federal judge has vacated the FDA’s LDT rule, The Dark Report analyzes the judgement and notes the various steps the FDA could take in response. Also, lab testing at pharmacies is proving to be less successful than was once anticipated.
See the full table of contentsHow Much Laboratory Business Intelligence Have You Missed?
Lab leaders rely on THE DARK REPORT for actionable intelligence on important developments in the business of laboratory testing. Maximize the money you make-and the money you keep! Best of all, it is released every three weeks!
Sign up for TDR Insider
Join the Dark Intelligence Group FREE and get TDR Insider FREE!
Never miss a single update on the issues that matter to you and your business.
Topics
- Anatomic Pathology
- Clinical Chemistry
- Clinical Laboratory
- Clinical Laboratory Trends
- Digital Pathology
- Genetic Testing
- In Vitro Diagnostics
- IVD/Lab Informatics
- Lab Intelligence
- Lab Marketplace
- Lab Risk & Compliance
- Laboratory Automation
- Laboratory Billing
- Laboratory Compliance
- Laboratory Equipment
- Laboratory Information Systems
- Laboratory Management
- Lean Six Sigma
- Managed Care Contracts
- Molecular Diagnostics
- Pathology Trends
- People
- Uncategorized